IDNA - Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

• A phase 2/3 trial failure in the MDD indication of PRAX-114 allows this biotech to shift focus over to PRAX-944 for Essential tremors and other preclinical drugs.
• Results from the phase 2b Essential1 study using PRAX-944 for treatment of patients with essential tremors expected 2nd half of 2022; preliminary results already released from phase 2a study.
• Praxis given go ahead to initiate phase 2 study using PRAX-944 for the treatment of patients with Parkinson's Disease; Study expected to begin 2nd half of 2022.
• Praxis had $222.5 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.

For further details see: